MDM2 and cancer: Therefore, if p53 activation is to be exploited as a cancer therapy, it is critical to find compound combinations that reduce the dose of mdm2 inhibitors required, while also enhancing their ability to kill cells rather than inducing their reversible cell cycle arresting effects.